Severe infection including disseminated herpes zoster triggered by subclinical Cushing’s disease: a case report

[1] Lacroix A(2015)Cushing’s syndrome Lancet 386 913-27

[2] Feelders RA(2001)Preclinical Cushing disease Arch Intern Med 161 892-3

[3] Stratakis CA(2003)A case of preclinical Cushing’s disease, accompanied with thyroid papillary carcinoma and adrenal incidentaloma Endocr J 50 325-31

[4] Nieman LK(2014)Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study Lancet Diabetes Endocrinol 2 396-405

[5] Takao T(2020)Approach to the patient with subclinical Cushing’s syndrome Curr Pharm Des 26 5584-90

[6] Mimoto T(2015)The treatment of Cushing’s disease Endocr Rev 36 385-486

[7] Yamamoto M(2013)Evaluation of the diagnostic criteria for Cushing’s disease in Japan Endocr J 60 127-35

[8] Hashimoto K(2013)Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up Eur J Endocrinol 169 715-23

[9] Kageyama K(2014)Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas J Clin Endocrinol Metab 99 4462-70

[10] Moriyama T(2018)A fatal case of atypical disseminated herpes zoster in a patient with meningoencephalitis and seizures associated with steroid immunosuppression Am J Case Rep 19 1162-7

[1] Lacroix A(2015)Cushing’s syndrome Lancet 386 913-27

[2] Feelders RA(2001)Preclinical Cushing disease Arch Intern Med 161 892-3

[3] Stratakis CA(2003)A case of preclinical Cushing’s disease, accompanied with thyroid papillary carcinoma and adrenal incidentaloma Endocr J 50 325-31

[4] Nieman LK(2014)Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study Lancet Diabetes Endocrinol 2 396-405

[5] Takao T(2020)Approach to the patient with subclinical Cushing’s syndrome Curr Pharm Des 26 5584-90

[6] Mimoto T(2015)The treatment of Cushing’s disease Endocr Rev 36 385-486

[7] Yamamoto M(2013)Evaluation of the diagnostic criteria for Cushing’s disease in Japan Endocr J 60 127-35

[8] Hashimoto K(2013)Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up Eur J Endocrinol 169 715-23

[9] Kageyama K(2014)Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas J Clin Endocrinol Metab 99 4462-70

[10] Moriyama T(2018)A fatal case of atypical disseminated herpes zoster in a patient with meningoencephalitis and seizures associated with steroid immunosuppression Am J Case Rep 19 1162-7